CD44-DT regulates p21-dependent senescence via interacting with AR-PCNA complex, revealing a therapeutic vulnerability to chimeric ncRNA-mediated AR degradation in prostate cancer
En palabras de los autores
Aberrant androgen receptor (AR) signaling driven by androgens plays a critical role in prostate cancer (PCa) progression. Interestingly, bipolar androgen therapy (BAT), a novel therapeutic strategy with cycles between near-castrate and supraphysiological androgen levels (SAL), suppresses PCa growth. SAL induces cellular senescence in various PCa models mediated by the AR, activation of AKT signaling and hypophosphorylation of pRb. Here, we show that SAL upregulates the lncRNA CD44-DT, the CD44 divergent transcript, in PCa cells linking CD44-DT to AR signaling. Knockdown and overexpression datasets suggest that CD44-DT supresses SAL-induced senescence as a negative feed-back loop. Transcriptome, ATAC-seq, and ChIP-seq analyses of PCa cells reveal that AR is recruited to the first intron of CD44 gene locus. Transcriptome analyses of the knockdown suggests that members of AP-1 family act in concert with AR as an upstream activator of CD44-DT. Accordingly, inhibition of the AP-1 complex by a small molecule inhibitor results in downregulation of CD44-DT expression, enhanced SAL-induced senescence and reduced proliferation. Mechanistically, CD44-DT physically interacts with PCNA and AR. This interaction facilitates p21 tumor suppressor degradation, permits cyclin-CDK activation, retinoblastoma (Rb) hyperphosphorylation activation of the AKT-p70S6K pathway. These findings suggest that CD44-DT is part of AR signaling and acts as a novel onco-lncRNA that is upregulated by AR. To validate the role of AR, we engineered a chimeric ncRNA capable degrading the AR as a novel type of RNA-PROTAC. Accordingly, this RNA-based AR-degrader downregulates CD44-DT confirming AR regulation of CD44-DT. Interestingly, the RNA-PROTAC potently induces apoptosis. Thus, the data suggest that CD44-DT is a novel direct AR target gene that modulates PCNA and p21 protein stability identifying a novel negative feed-back loop at the crossroad between proliferation and senescence indicating CD44-DT as a potential therapeutic target for PCa.
Apareció: jueves, 19 de noviembre. bioRxiv. Preprint, todavía sin revisión por pares.